Integrin receptor antagonists
    2.
    发明授权
    Integrin receptor antagonists 失效
    整合素受体拮抗剂

    公开(公告)号:US5760028A

    公开(公告)日:1998-06-02

    申请号:US770538

    申请日:1996-12-20

    CPC分类号: C07D401/12 C07D403/12

    摘要: This invention relates to novel heterocycles including 3-�1-�3-(imidazolin-2-ylamino)propyl!indazol-5-ylcarbonylamino!-2-(benzyloxycarbonylamino)propionic acid, which are useful as antagonists of the .alpha..sub.v .beta..sub.3 integrin and related cell surface adhesive protein receptors, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of cell adhesion, the treatment of angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, thrombosis, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis.

    摘要翻译: 本发明涉及包含3- [1- [3-(咪唑啉-2-基氨基)丙基]吲唑-5-基羰基氨基] -2-(苄氧基羰基氨基)丙酸的新型杂环,其可用作αvβ3的拮抗剂 整合素和相关细胞表面粘附蛋白受体,含有这些化合物的药物组合物,制备这些化合物的方法,以及使用这些化合物单独或与其它治疗剂组合用于抑制细胞粘附,血管生成 疾病,炎症,骨退化,癌转移,糖尿病性视网膜病变,血栓形成,再狭窄,黄斑变性以及由细胞粘附和/或细胞迁移和/或血管发生介导的其它病症。